Dr. Leslie Sloan Ph.D. serves as Chief Operating Officer of the Company. Prior to joining Aeglea, between March 2012 and April 2017, Dr. Sloan served in various roles of increasing responsibility at Ipsen Bioscience Inc., a biopharmaceutical company, including as Senior Director: Head of R&D Operational Excellence, Vice President, R&D Project Management & Analytics, leading the strategic and operational execution of its global R&D portfolio and President of Ipsen Bioscience, Inc. Prior to that, Dr. Sloan also served as Senior Director at Pfizer, where she was a member of the R&D clinical candidate survival council and candidate quality guidelines committee. Dr. Sloan holds a B.S. in chemistry and medical biology from Southeastern Oklahoma State University and a Ph.D. in bio-organic chemistry from Yale University.
As the Chief Operating Officer of Aeglea BioTherapeutics Inc, the total compensation of Leslie Sloan at Aeglea BioTherapeutics Inc is $1,149,220. There are 1 executives at Aeglea BioTherapeutics Inc getting paid more, with Anthony Quinn having the highest compensation of $2,482,780.
Leslie Sloan is 49, he's been the Chief Operating Officer of Aeglea BioTherapeutics Inc since 2019. There are 10 older and 4 younger executives at Aeglea BioTherapeutics Inc. The oldest executive at Aeglea BioTherapeutics Inc is V. Bryan Lawlis, 68, who is the Independent Director.
Leslie's mailing address filed with the SEC is 805 LAS CIMAS PARKWAY, SUITE 100, AUSTIN, TX, 78746.
Over the last 9 years, insiders at Aeglea BioTherapeutics Inc have traded over $1,425,674 worth of Aeglea BioTherapeutics Inc stock and bought 1,931,829 units worth $12,152,489 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Bioventures Ltd Novartis Ag... oraz Advisors Llc Orbi Med Capit.... On average, Aeglea BioTherapeutics Inc executives and independent directors trade stock every 70 days with the average trade being worth of $864,564. The most recent stock trade was executed by Marcio Souza on 25 August 2022, trading 90,000 units of AGLE stock currently worth $50,400.
aeglea was founded in december of 2013 to develop engineered human enzymes invented in the laboratory of george georgiou, ph.d. of the university of texas at austin. the convergence of discovery and technology has created a significant opportunity for aeglea to impact both the treatment of inborn errors of metabolism and cancer. three drug candidates that degrade specific amino acids in the circulation are in development. for inborn errors of metabolism efforts are underway to normalize high arginine levels in patients who suffer from a gene mutation in the arginine degrading enzyme arginase1 and for patients who have mutations leading to excess levels of homocysteine. taking advantage of a cancer’s metabolic vulnerability and selectively killing only the tumor through deprivation of arginine, cysteine/cystine, and methionine are techniques in development for multiple oncology indications. coupling amino acid depletion therapy with the development of diagnostics for each oncology f
Aeglea BioTherapeutics Inc executives and other stock owners filed with the SEC include: